Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

Journal of Medical Economics

Volumn 16, Issue 9, 2013, Pages 1163-1168

  Deitelzweig, Steve ^a   Amin, Alpesh ^b   Jing, Yonghua ^c   Makenbaeva, Dinara ^c   Wiederkehr, Daniel ^d   Lin, Jay ^e   Graham, John ^c  

^a OCHSNER CLINIC FOUNDATION   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRISTOL MYERS SQUIBB   (United States)

^d PFIZER INC   (United States)

^e Novosys Health   (United States)

Author keywords

Atrial fibrillation; Medical costs; Oral anticoagulants; Stroke prevention; Warfarin

Indexed keywords

APIXABAN; DABIGATRAN; RIVAROXABAN; WARFARIN;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; CARDIAC PATIENT; CEREBROVASCULAR ACCIDENT; DEEP VEIN THROMBOSIS; DRUG EFFICACY; EMBOLISM; GROUPS BY AGE; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; POPULATION RESEARCH; UNITED STATES;

ADMINISTRATION, ORAL; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; COST SAVINGS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG UTILIZATION; FEMALE; HUMANS; MALE; MORPHOLINES; PYRAZOLES; PYRIDONES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; STROKE; THIOPHENES; UNITED STATES; WARFARIN;

EID: 84882974921     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.826664     Document Type: Article

References (25)

1. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006;114:119-25 (Pubitemid 44420743)
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5 (Pubitemid 32424106)
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8
4. Naccarelli GV, Varker H, Lin J, et al. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9
5. Kim MH, Lin J, Hussein M, et al. Cost of atrial fibrillation in United States managed care organizations. Adv Ther 2009;26:847-57
6. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007;146:857-67 (Pubitemid 351650486)
7. Singer DE, Albers GW, Dalen JE, et al; American College of Chest Physicians. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008;133:546S-92S (Pubitemid 351892972)
8. Birman-Deych E, Radford MJ, Nilasena DS, et al. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke 2006;37:1070-4
9. Fustinoni O. The case for an elderly targeted stroke management. Front Neurol 2011;2:89-1074
10. Agarwal S, Bennett D, Smith DJ. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting. Am J Cardiovasc Drugs 2010;10:37-48
11. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in patients with atrial fibrillation. New Engl J Med 2011;365:981-2
12. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. New Engl J Med 2009;361:1139-51
13. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus Warfarin in nonvalvular atrial fibrillation. New Engl J Med 2011;365:883-91
14. Deitelzweig S, Amin A, Jing Y, et al. Medical cost reductions associated with the usage of novel oral anticoagulants vs. warfarin among atrial fibrillation patients, based on the RE-LY, ROCKET-AF and ARISTOTLE Trials. J Med Econ 2012;15:776-85.
15. Bureau of Labor Statistics US Department of Labor. Consumer Price Index December 2010. USDL-11-0018. 2010. Washington DC. http://www.bls.gov/news. release/archives/cpi-01142011.pdf. Accessed January 11, 2012
16. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of anticoagulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke 2011;42:112-8
17. Sorensen SV, Kansal AR, Connolly S, et al. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: a Canadian payer perspective. Throm Haemost 2011;105:908-19
18. Earnshaw SR, Scheiman J, Fendrick AM, et al. Cost-utility of aspirin and proton pump inhibitors for primary prevention. Arch Intern Med 2011;171:218-25
19. Spyropoulos AC, Lin J. Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations. J Manag Care Pharm 2007;13:475-86 (Pubitemid 350193368)
20. Center for Medicare and Medicaid Services. Medicare Fee Schedule, Payment and Reimbursement Benefit Guideline, CPT Code Billing: Medicare Fee Schedule for Office Visit CPT Codes-2011, CPT Code 99213, 99214, 99203. 2011. Baltimore, MD. http://www.medicarepaymentandreimbursement. com/p/medicare-fee-schedule-for- office-visit.html. Accessed February 29, 2012
21. Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med 2011;364:806-17
22. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 2007;115:2689-96 (Pubitemid 46842784)
23. Analy$ource Online. First Databank Inc. San Francisco, CA. 2013. DMD America, Syracuse, NY
24. Harrington AR, Armstrong EP, Nolan Jr PE, et al. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation. Stroke 2013;44:1676-81
25. The Henry J Kaiser Family Foundation. U.S. health care costs: issue modules, background brief. 2012. Menlo Park, CA. http://www.kaiseredu.org/Issue- Modules/US-Health-Care-Costs/Background-Brief.aspx. Accessed March 2, 2012